Pigmentation refers to the natural coloring of skin of animal or human. Pigmentation disorders result from altering melanin level, a pigment generated by melanocytes. Pigmentation disorders impact the skin color making the skin look blotchy and discolored. Hypopigmentation is skin patches that are lighter than the whole tone of skin. It can result from the deficiency of melanin pigment owing to disease, burns, injury, or other trauma. These disorders consist of albinism and vitiligo.
The global hypopigmentation disorder treatment market is projected to witness substantial growth during the forecast period owing to factors such as improvements & advancements in terms of technology in healthcare infrastructure and the escalating count of clinical trials to obtain effective treatment solutions for hypopigmentation disorders. The flourishing pharmaceutical industry across the world will indirectly drive the global market growth. In addition, the market demand is also likely to be fueled by the growing incidence of vitiligo and accessibility of cost-effective treatment choices. Further, increasing need for affordable and effective to treat hypopigmentation disorders is projected to offer the market players with numerous prospects for business expansion.
The global hypopigmentation disorder treatment market can be grouped based on disease indication, treatment, end user, and geography. The market, on the basis of treatment, is segregated into laser therapy, topical drugs, microdermabrasion, chemical peels, and others. The market, on the basis of disease indication, is bifurcated into albinism, vitiligo, and others. The market, on the basis of end user, is divided into dermatology clinics, aesthetic clinics, hospitals, and others.
Region-wise, North America is projected to govern the global hypopigmentation disorder treatment market during the forecast period driven by rising prevalence of hypopigmentation disorders, strong product pipeline, new product approvals, and a rise in healthcare spending. As per National Organization for Albinism and Hypopigmentation, around 1 in 20,000 people have some kind of albinism in the US. Further, the market is also expected to be fueled by improvement in cosmetic therapy like laser resurfacing and constant R&D on pigmentation disorder surgeries & treatment. Asia Pacific is also projected to witness lucrative growth during the near future owing to the altering lifestyle and increasing disposable income. China has a high pool of patients suffering from vitiligo.
The key players functional in the global hypopigmentation disorder treatment market comprise SkinCeuticals, Allergan, Episciences, Inc., Pierre Fabre, Obagi Cosmeceuticals LLC (Obagi Medical), RXi Pharmaceuticals Corporation, and Alvogen, among others. These firms have implemented the approach of collaboration and acquisition to fortify their status in the worldwide market. To cite, Allergan Plc., in Sept 2018, agreed to purchase a privately held clinical-stage biotechnology firm, Bonti, Inc., which focuses on the commercialization and development of new, fast-acting neurotoxin programs for therapeutic and aesthetic applications.
Get Sample of this Research Report – https://www.zionmarketresearch.com/sample/hypopigmentation-disorder-treatment-market
